Butterfly Network Director Phanstiel Buys $1.0 Million in Stock. Is This a Sign Investors Should Also Buy?

Director Louise S. Phanstiel purchased 115,200 shares of Butterfly Network, Inc. (NYSE:BFLY) in an indirect transaction on August 14, 2026. SEC Form 4 filing.

Transaction summary

Transaction value based on SEC Form 4 weighted average purchase price ($8.68); post-transaction value based on the August 14, 2026 market close ($8.84).

Key questions

• What are the specific execution details of this purchase?
  The transaction was completed at a weighted-average price of $8.68 per share, with individual trade prices ranging from $8.49 to $8.865 per share. All shares in this filing were acquired for the Phanstiel Trust, an entity that now holds approximately 43% of the director's total equity stake.
• How does this move impact the insider's overall alignment with shareholders?
  By increasing her total position to 691,413 shares, Louise S. Phanstiel has reached a total beneficial ownership level representing 0.26% of the company. The purchase marks a substantial increase in the trust-held portion of her portfolio while maintaining a separate direct holding of ~391,000 shares.
• What is the company's current financial profile and scale?
  Butterfly Network operates with a market capitalization of $2.4 billion as of the Aug. 14, 2026 market close. The medical device company reported trailing twelve-month revenue of $112.1 million and a net income loss of $74.8 million over the same period.

Company Overview

Company Snapshot

• Butterfly Network specializes in the design, manufacture, and global commercialization of advanced ultrasound imaging technologies, with its core product portfolio including the portable Butterfly iQ single-probe system for whole-body ultrasound imaging and the Butterfly iQ+, a point-of-care ultrasound device with smartphone and tablet connectivity.
• The company operates a direct-to-customer and institutional sales model, generating revenue through the sale of proprietary ultrasound devices and associated software platforms that enable point-of-care diagnostics across clinical and non-clinical settings.
• Butterfly Network's primary customer base encompasses hospitals, clinics, emergency departments, and individual healthcare practitioners globally, with a strategic focus on expanding access to portable ultrasound imaging in underserved markets and emerging economies.

Butterfly Network is a digital health enterprise with a market capitalization of $2.4 billion, operating with 220 employees from its Burlington, Mass., headquarters. The company has demonstrated significant momentum, with TTM revenue of $112.1 million, though it remains in a net loss position as it scales its commercialization efforts. Butterfly Network's competitive differentiation lies in its proprietary semiconductor-based ultrasound technology, which enables unprecedented portability and ease of use, positioning the company to capture market share in the global point-of-care ultrasound market.

What this transaction means for investors

Phanstiel is the chair of the Board of Directors of Myriad Genetis and a board member there since September 2009. She has also held several executive positions at Anthem, Inc from 1996 to 2007. Clearly, she knows healthcare.

There are many reasons an insider may sell shares in a company. One reason could be the need to raise cash to fund a large personal expense. Another reason could be for a reasonable portfolio diversification unrelated to their outlook for the company. A third reason could be what investors fear most: a bearish outlook on the company's future.

However, there is only one reason an insider buys stock: they believe the share price is going up.

By that rule of thumb alone, Phanstiel's purchase of Butterfly Network shares is a bullish signal. That she is a knowledgeable person in the sector the company participates in adds to the bullishness. Those signals are further bolstered by studies showing that, more often than not, an insider purchase predicts a higher share price 30 days later.

There are more reasons than insider buying to be bullish. Wall Street analysts see Butterfly Networks' revenue rising 19% in the current fiscal year to $97.1 million. That rise will come with a narrowing of the net loss by about one third. By 2028, analkysts expects BFLY to double its revenue for 2026 levels and have a much lower net loss. Thing sare looking up.

An insider purchase like Phanstiel's may not be a slam-dunk call to action, but it is a signal to investors to explore the bullish indicators the company is showing.

Brendan Coffey has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.